Post-transplantation diabetes is better controlled after conversion from prednisone to deflazacort: A prospective trial in renal transplants

Yu Seun Kim, Myoung Soo Kim, Soon Il Kim, Seung Kil Lim, Ho Yung Lee, Dae Suk Han, Kiil Park

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

It is well known that long-term use of steroids plays a decisive role in the development of glucose intolerance and diabetes mellitus (DM). Deflazacort, an oxazoline derivative of prednisolone, has been introduced as a potential substitute for conventional steroids in order to ameliorate glucose intolerance. We initiated a randomized study of conversion from prednisone to deflazacort in kidney transplantation (Tx) recipients presenting with pre-Tx or post-Tx DM to ascertain whether or not the switch to deflazacort would ameliorate the diabetic state. Forty-two recipients in the conversion group were compared with 40 patients on prednisone (the control group) in a prospective manner. The dose reduction of insulin or oral blood glucose-lowering agents, the adequacy of glucose control, and the development of side effects were the criteria for evaluating outcome. In the conversion group, patients were switched to deflazacort at a dose ratio of 6 mg deflazacort to 5 mg prednisone. During the mean follow-up period of 13.2 months, neither graft dysfunction nor acute rejection developed in the conversion group. Improvement in blood glucose control in the conversion group was noted. When the conversion group was stratified into pre- or post-Tx DM, promising effects were clearly evident in the post-Tx DM patients. More than 50% dose reduction of blood glucose-lowering agents was possible in 42.3% of post-Tx DM patients. In conclusion, it was readily possible to control blood glucose better in post-Tx DM recipients without seriously affecting the immunosuppressive activity after conversion to deflazacort.

Original languageEnglish
Pages (from-to)197-201
Number of pages5
JournalTransplant International
Volume10
Issue number3
DOIs
Publication statusPublished - 1997 May 1

Fingerprint

Prednisone
Diabetes Mellitus
Transplantation
Transplants
Kidney
Blood Glucose
Glucose Intolerance
Steroids
Immunosuppressive Agents
Prednisolone
Kidney Transplantation
deflazacort
Insulin
Glucose
Control Groups

All Science Journal Classification (ASJC) codes

  • Transplantation

Cite this

@article{7a8a0719df08469197cba94196592607,
title = "Post-transplantation diabetes is better controlled after conversion from prednisone to deflazacort: A prospective trial in renal transplants",
abstract = "It is well known that long-term use of steroids plays a decisive role in the development of glucose intolerance and diabetes mellitus (DM). Deflazacort, an oxazoline derivative of prednisolone, has been introduced as a potential substitute for conventional steroids in order to ameliorate glucose intolerance. We initiated a randomized study of conversion from prednisone to deflazacort in kidney transplantation (Tx) recipients presenting with pre-Tx or post-Tx DM to ascertain whether or not the switch to deflazacort would ameliorate the diabetic state. Forty-two recipients in the conversion group were compared with 40 patients on prednisone (the control group) in a prospective manner. The dose reduction of insulin or oral blood glucose-lowering agents, the adequacy of glucose control, and the development of side effects were the criteria for evaluating outcome. In the conversion group, patients were switched to deflazacort at a dose ratio of 6 mg deflazacort to 5 mg prednisone. During the mean follow-up period of 13.2 months, neither graft dysfunction nor acute rejection developed in the conversion group. Improvement in blood glucose control in the conversion group was noted. When the conversion group was stratified into pre- or post-Tx DM, promising effects were clearly evident in the post-Tx DM patients. More than 50{\%} dose reduction of blood glucose-lowering agents was possible in 42.3{\%} of post-Tx DM patients. In conclusion, it was readily possible to control blood glucose better in post-Tx DM recipients without seriously affecting the immunosuppressive activity after conversion to deflazacort.",
author = "Kim, {Yu Seun} and Kim, {Myoung Soo} and Kim, {Soon Il} and Lim, {Seung Kil} and Lee, {Ho Yung} and Han, {Dae Suk} and Kiil Park",
year = "1997",
month = "5",
day = "1",
doi = "10.1007/s001470050041",
language = "English",
volume = "10",
pages = "197--201",
journal = "Transplant International",
issn = "0934-0874",
publisher = "Wiley-Blackwell",
number = "3",

}

Post-transplantation diabetes is better controlled after conversion from prednisone to deflazacort : A prospective trial in renal transplants. / Kim, Yu Seun; Kim, Myoung Soo; Kim, Soon Il; Lim, Seung Kil; Lee, Ho Yung; Han, Dae Suk; Park, Kiil.

In: Transplant International, Vol. 10, No. 3, 01.05.1997, p. 197-201.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Post-transplantation diabetes is better controlled after conversion from prednisone to deflazacort

T2 - A prospective trial in renal transplants

AU - Kim, Yu Seun

AU - Kim, Myoung Soo

AU - Kim, Soon Il

AU - Lim, Seung Kil

AU - Lee, Ho Yung

AU - Han, Dae Suk

AU - Park, Kiil

PY - 1997/5/1

Y1 - 1997/5/1

N2 - It is well known that long-term use of steroids plays a decisive role in the development of glucose intolerance and diabetes mellitus (DM). Deflazacort, an oxazoline derivative of prednisolone, has been introduced as a potential substitute for conventional steroids in order to ameliorate glucose intolerance. We initiated a randomized study of conversion from prednisone to deflazacort in kidney transplantation (Tx) recipients presenting with pre-Tx or post-Tx DM to ascertain whether or not the switch to deflazacort would ameliorate the diabetic state. Forty-two recipients in the conversion group were compared with 40 patients on prednisone (the control group) in a prospective manner. The dose reduction of insulin or oral blood glucose-lowering agents, the adequacy of glucose control, and the development of side effects were the criteria for evaluating outcome. In the conversion group, patients were switched to deflazacort at a dose ratio of 6 mg deflazacort to 5 mg prednisone. During the mean follow-up period of 13.2 months, neither graft dysfunction nor acute rejection developed in the conversion group. Improvement in blood glucose control in the conversion group was noted. When the conversion group was stratified into pre- or post-Tx DM, promising effects were clearly evident in the post-Tx DM patients. More than 50% dose reduction of blood glucose-lowering agents was possible in 42.3% of post-Tx DM patients. In conclusion, it was readily possible to control blood glucose better in post-Tx DM recipients without seriously affecting the immunosuppressive activity after conversion to deflazacort.

AB - It is well known that long-term use of steroids plays a decisive role in the development of glucose intolerance and diabetes mellitus (DM). Deflazacort, an oxazoline derivative of prednisolone, has been introduced as a potential substitute for conventional steroids in order to ameliorate glucose intolerance. We initiated a randomized study of conversion from prednisone to deflazacort in kidney transplantation (Tx) recipients presenting with pre-Tx or post-Tx DM to ascertain whether or not the switch to deflazacort would ameliorate the diabetic state. Forty-two recipients in the conversion group were compared with 40 patients on prednisone (the control group) in a prospective manner. The dose reduction of insulin or oral blood glucose-lowering agents, the adequacy of glucose control, and the development of side effects were the criteria for evaluating outcome. In the conversion group, patients were switched to deflazacort at a dose ratio of 6 mg deflazacort to 5 mg prednisone. During the mean follow-up period of 13.2 months, neither graft dysfunction nor acute rejection developed in the conversion group. Improvement in blood glucose control in the conversion group was noted. When the conversion group was stratified into pre- or post-Tx DM, promising effects were clearly evident in the post-Tx DM patients. More than 50% dose reduction of blood glucose-lowering agents was possible in 42.3% of post-Tx DM patients. In conclusion, it was readily possible to control blood glucose better in post-Tx DM recipients without seriously affecting the immunosuppressive activity after conversion to deflazacort.

UR - http://www.scopus.com/inward/record.url?scp=0030951564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030951564&partnerID=8YFLogxK

U2 - 10.1007/s001470050041

DO - 10.1007/s001470050041

M3 - Article

C2 - 9163859

AN - SCOPUS:0030951564

VL - 10

SP - 197

EP - 201

JO - Transplant International

JF - Transplant International

SN - 0934-0874

IS - 3

ER -